Results 101 to 110 of about 3,765,002 (291)

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

open access: yesMolecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller   +10 more
wiley   +1 more source

Targeting senescent cells in translational medicine

open access: yesEMBO Molecular Medicine, 2019
Organismal ageing is a complex process driving progressive impairment of functionality and regenerative potential of tissues. Cellular senescence is a state of stable cell cycle arrest occurring in response to damage and stress and is considered a ...
Marta Paez‐Ribes   +3 more
doaj   +1 more source

Antibiofilm Technology

open access: yes, 2017
The 2017 Translational Medicine Symposium was held on Feb. 27th. The symposium addressed how clinicians\u27 ideas and research results can have an impact on patient care - if they are translated into clinical practice.
Ryan Looper, PhD
core  

Circulating microRNA signatures of cachexia and cancer in Canis familiaris as a comparative oncology model for human disease

open access: yesMolecular Oncology, EarlyView.
Circulating microRNAs as biomarkers of cachexia and sex‐specific cancer in senior dogs. In 25 client‐owned dogs, four circulating miRNAs (miR‐15a, miR‐15b, miR‐16, miR‐140) were downregulated in cachexia, with miR‐16 the strongest individual biomarker (AUC = 0.899).
Soon‐Seok Park   +6 more
wiley   +1 more source

Antibody-based Diagnostics

open access: yes, 2017
The 2017 Translational Medicine Symposium was held on Feb. 27th. The symposium addressed how clinicians\u27 ideas and research results can have an impact on patient care - if they are translated into clinical practice.
Shawn Owen, PhD
core  

Epigenetic silencing of the liver‐specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation

open access: yesMolecular Oncology, EarlyView.
LUNAR is a liver‐specific long noncoding RNA (lncRNA) that is highly expressed in normal liver but becomes epigenetically silenced in hepatocellular carcinoma through promoter hypermethylation. Loss of LUNAR is associated with NOTCH activation, epithelial–mesenchymal transition, and metastasis, whereas restoring LUNAR restrains metastatic progression ...
Se Ha Jang   +9 more
wiley   +1 more source

The Memory Care Navigator

open access: yes, 2017
The 2017 Translational Medicine Symposium was held on Feb. 27th. The symposium addressed how clinicians\u27 ideas and research results can have an impact on patient care - if they are translated into clinical practice.
Troy Andersen, PhD, MSW, MS, LCSW
core  

Translating whole‐genome doubling into precision medicine in cancer

open access: yesMolecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Entrepreneurism in Medical Device Development An Evolutionary Path

open access: yes, 2017
The 2017 Translational Medicine Symposium was held on Feb. 27th. The symposium addressed how clinicians\u27 ideas and research results can have an impact on patient care - if they are translated into clinical practice.
Derek Sakata, MD
core  

A brilliant dawn and an even brighter future for Annals of Translational Medicine

open access: yes, 2019
A brilliant dawn and an even brighter future for Annals of Translational ...
Lippi, Giuseppe
core   +1 more source

Home - About - Disclaimer - Privacy